Weakness in American Century International Gr Inv's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative. Morningstar Manager Research Summary ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

The sales come as INV, currently valued at $176 million, has seen its stock decline nearly 75% year-to-date, trading well below its 52-week high of $14.95. The sales occurred between October 22 and ...

Real time quote data is not available at this time. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

COLUMBUS, OH., August 25, 2022 - Invirsa today announced that it has submitted to the US Food and Drug Administration (FDA) an investigational new drug (IND) application for its lead compound, INV-102 ...

American Century Small Cap Value Inv earns a Morningstar Medalist Rating of Neutral with strength in areas such as People offset by weaker spots such as Process.

Jindal Poly Inv Share: compare Jindal Poly Inv with up to two competing stocks only on Moneycontrol. Use our stock comparison tool to check price, market cap, returns & more ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Invirsa Inc., a privately held, clinical-stage pharmaceutical company focused on developing an innovative topically administered eyedrop formulation INV-102 for ocular ...

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with ...